SignaBlok raised $0.15 million to develop targeted peptide therapeutics and integrated delivery systems that block cell receptor signaling, enabling innovative treatments for serious diseases with unmet medical needs, including scleroderma.
SignaBlok raised $0.15 million to develop targeted peptide therapeutics and integrated delivery systems that block cell receptor signaling, enabling innovative treatments for serious diseases with unmet medical needs, including scleroderma.
